Ovarian Cancer Disease Burden Affects Survival Despite R0 Resection


Despite achieving complete surgical resection, advanced epithelial ovarian cancer or primary peritoneal cancer patients with a high disease burden had worse survival outcomes than those with lower disease burden.

Despite achieving complete surgical resection, women who underwent resection of advanced epithelial ovarian cancer or primary peritoneal cancer with a high preoperative disease burden had worse progression-free and overall survival than those with lower disease burden, results of a large multi-institutional study showed.

“We showed that both higher disease score and increased residual disease resulted in worse outcome compared with patients with less disease distribution before and after surgery,” wrote researchers led by Neil S. Horowitz, MD, of Brigham and Women’s Hospital, Boston, in the Journal of Clinical Oncology.

Looking at 2,655 patients with advanced epithelial ovarian cancer or primary peritoneal cancer from the Gynecologic Oncology Group 182 study, the researchers collected demographic, pathologic, surgical, and outcome data. Included women had achieved complete resection or residual disease of < 1 cm (MR). The researchers goal was to determine the effects of preoperative disease burden and complex surgery on residual disease and survival outcomes in this patient population.

As expected, Horowitz and colleagues found that patients with MR had a worse prognosis than did those patients who achieved complete resection, having worse progression-free survival (15 months vs 29 months; P < .01) and overall survival (41 months vs 77 months; P < .01).

In addition, those patients with the highest disease burden prior to surgery had significantly worse progression-free survival (15 months vs 23 or 34 months; P < .01) and overall survival (40 months vs 71 or 86 months; P < .01) compared with patients with either a moderate or low disease score. This worse prognosis remained even when the researchers looked at only those patients able to achieve complete resection.

“Although we were investigating a subset of patients from GOG-182 (< 1 cm of residual disease), we found that when we restricted our multivariable analysis to only those institutions that achieved complete resection in > 40% of patients with < 1 cm residual disease, our conclusions were not changed,” the researchers noted.

According to the study, there has been an increased trend toward aggressive primary debulking surgery for women with advanced epithelial ovarian cancer or primary peritoneal cancer, and based on these results, this approach makes sense for those women with low or moderate preoperative disease burden.

“We suggest the consideration of (and additional studies should explore) a potential paradigm shift, in which, if R0 is difficult to attain at primary cytoreduction, use of neoadjuvant chemotherapy with interval debulking to allow for R0 may be superior to primary surgery after which the patient is left with gross residual disease,” the researchers wrote.

Related Videos
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content